Soufflé Therapeutics
- Health & Biotech
- Watertown, MA, US
- Private
- souffletx.com
Watertown, MA biotech developing RNA medicines, with lead programs for muscular dystrophy, heart failure and metabolic disease.
$135MEquity raised in 2025–20262025 — · 2026 $135M · 1 equity round
$135MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 1 source
Earlier rounds not yet sourced. Soufflé Therapeutics raised before 13 Oct 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series BAmount$135MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 13
- Juvia Group1
- Amgen Ventures
- ARCH Venture Partners
- Balyasny Asset Management
- BB Biotech
- Bessemer Venture Partners
- Breyer Capital
- Fidelity
- Invus
- Janus Henderson Investors
- Leaps by Bayer
- TCG Crossover Management
- Temasek
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
Parabilis MedicinesHealth · $975M in 2025–2026Shared: Fidelity, ARCH Venture Partners +2AnthropicAI Labs · $113B in 2025–2026Shared: Fidelity, Bessemer Venture Partners +1Nearfield InstrumentsDeep Tech · $380M in 2025–2026Shared: Fidelity, TemasekWaymoRobotics · $16B in 2025–2026Shared: Fidelity, Bessemer Venture Partners +1DatabricksEnterprise · $10B in 2025–2026Shared: Fidelity, TemasekLegoraAI Apps · $1.4B in 2025–2026Shared: Fidelity, Bessemer Venture Partners
Also in the Watertown hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Soufflé Therapeutics and its logo are trademarks of their owners, used here for identification only.
